(MAZE) Maze Therapeutics, Common - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5787841007
Stock: Small Molecules, Kidney Disease, Metabolic Disease, Obesity
Total Rating 48
Risk 89
Buy Signal 1.92
| Risk 5d forecast | |
|---|---|
| Volatility | 64.4% |
| Relative Tail Risk | -8.36% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.92 |
| Alpha | 302.88 |
| Character TTM | |
|---|---|
| Beta | 1.243 |
| Beta Downside | 0.922 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.69% |
| CAGR/Max DD | 3.56 |
EPS (Earnings per Share)
Revenue
Description: MAZE Maze Therapeutics, Common March 04, 2026
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines.
The company targets renal, cardiovascular, metabolic diseases, and obesity. The biopharmaceutical sector is characterized by high research and development costs and lengthy drug approval processes.
Key pipeline assets include MZE829, a Phase II drug for APOL1 kidney disease, and MZE782, a Phase I drug for chronic kidney disease. They also have MZE001 for Pompe disease.
Maze Therapeutics operates under a business model common in biotech, where value is primarily derived from successful drug development and commercialization.
For more detailed financial and operational data, ValueRay offers comprehensive analytics.
Headlines to watch out for
- MZE829 Phase II trial results impact APOL1 kidney disease market entry
- MZE782 Phase I data influences chronic kidney disease pipeline
- MZE001 clinical progress affects Pompe disease treatment landscape
- Regulatory approvals for lead candidates determine market access
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -126.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.26 > 0.02 and ΔFCF/TA -65.70 > 1.0 |
| NWC/Revenue: 220.4% < 20% (prev 81.43%; Δ 139.0% < -1%) |
| CFO/TA -0.25 > 3% & CFO -106.7m > Net Income -126.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.8m) vs 12m ago 4.57% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 54.51% > 50% (prev 87.02%; Δ -32.51% > 0%) |
| Interest Coverage Ratio: -51.83 > 6 (EBITDA TTM -126.3m / Interest Expense TTM -2.49m) |
Altman Z'' -11.80
| A: 0.87 (Total Current Assets 391.3m - Total Current Liabilities 22.1m) / Total Assets 422.1m |
| B: -1.08 (Retained Earnings -455.0m / Total Assets 422.1m) |
| C: -0.42 (EBIT TTM -128.9m / Avg Total Assets 307.3m) |
| D: -10.67 (Book Value of Equity -454.9m / Total Liabilities 42.6m) |
| Altman-Z'' Score: -11.80 = D |
Beneish M
| DSRI: none (Receivables 700.0k/none, Revenue 167.5m/167.5m) |
| GMI: 1.00 (GM 98.78% / 98.38%) |
| AQI: 0.26 (AQ_t 0.01 / AQ_t-1 0.04) |
| SGI: 1.0 (Revenue 167.5m / 167.5m) |
| TATA: -0.05 (NI -126.1m - CFO -106.7m) / TA 422.1m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of MAZE shares?
As of March 11, 2026, the stock is trading at USD 51.06 with a total of 1,286,301 shares traded.
Over the past week, the price has changed by +15.56%, over one month by +5.55%, over three months by +32.23% and over the past year by +333.40%.
Over the past week, the price has changed by +15.56%, over one month by +5.55%, over three months by +32.23% and over the past year by +333.40%.
Is MAZE a buy, sell or hold?
Maze Therapeutics, Common has received a consensus analysts rating of 4.75.
Therefore, it is recommended to buy MAZE.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MAZE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53 | 3.8% |
| Analysts Target Price | 53 | 3.8% |
MAZE Fundamental Data Overview March 11, 2026
P/E Forward = 8.5324
P/S = 3.1363
P/B = 5.7068
Revenue TTM = 167.5m USD
EBIT TTM = -128.9m USD
EBITDA TTM = -126.3m USD
Long Term Debt = 24.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.76m USD (from shortTermDebt, last quarter)
Debt = 24.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -292.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.81b USD (2.17b + Debt 24.2m - CCE 383.9m)
Interest Coverage Ratio = -51.83 (Ebit TTM -128.9m / Interest Expense TTM -2.49m)
EV/FCF = -16.74x (Enterprise Value 1.81b / FCF TTM -108.0m)
FCF Yield = -5.97% (FCF TTM -108.0m / Enterprise Value 1.81b)
FCF Margin = -64.49% (FCF TTM -108.0m / Revenue TTM 167.5m)
Net Margin = -75.30% (Net Income TTM -126.1m / Revenue TTM 167.5m)
Gross Margin = unknown ((Revenue TTM 167.5m - Cost of Revenue TTM 2.04m) / Revenue TTM)
Tobins Q-Ratio = 4.28 (Enterprise Value 1.81b / Total Assets 422.1m)
Interest Expense / Debt = -10.28% (Interest Expense -2.49m / Debt 24.2m)
Taxrate = 2.19% (1.17m / 53.4m)
NOPAT = -126.1m (EBIT -128.9m * (1 - 2.19%)) [loss with tax shield]
Current Ratio = 17.70 (Total Current Assets 391.3m / Total Current Liabilities 22.1m)
Debt / Equity = 0.06 (Debt 24.2m / totalStockholderEquity, last quarter 379.4m)
Debt / EBITDA = 2.32 (negative EBITDA) (Net Debt -292.6m / EBITDA -126.3m)
Debt / FCF = 2.71 (negative FCF - burning cash) (Net Debt -292.6m / FCF TTM -108.0m)
Total Stockholder Equity = 282.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.05% (Net Income -126.1m / Total Assets 422.1m)
RoE = -44.62% (Net Income TTM -126.1m / Total Stockholder Equity 282.7m)
RoCE = -42.01% (EBIT -128.9m / Capital Employed (Equity 282.7m + L.T.Debt 24.2m))
RoIC = -81.00% (negative operating profit) (NOPAT -126.1m / Invested Capital 155.6m)
WACC = 10.38% (E(2.17b)/V(2.19b) * Re(10.50%) + (debt cost/tax rate unavailable))
Discount Rate = 10.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.26%
[DCF] Fair Price = unknown (Cash Flow -108.0m)
EPS Correlation: 83.60 | EPS CAGR: 0.0% | SUE: N/A | # QB: 0
Revenue Correlation: -13.63 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=-3.15 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=-2.5% | Growth Revenue=+0.0%
P/S = 3.1363
P/B = 5.7068
Revenue TTM = 167.5m USD
EBIT TTM = -128.9m USD
EBITDA TTM = -126.3m USD
Long Term Debt = 24.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.76m USD (from shortTermDebt, last quarter)
Debt = 24.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -292.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.81b USD (2.17b + Debt 24.2m - CCE 383.9m)
Interest Coverage Ratio = -51.83 (Ebit TTM -128.9m / Interest Expense TTM -2.49m)
EV/FCF = -16.74x (Enterprise Value 1.81b / FCF TTM -108.0m)
FCF Yield = -5.97% (FCF TTM -108.0m / Enterprise Value 1.81b)
FCF Margin = -64.49% (FCF TTM -108.0m / Revenue TTM 167.5m)
Net Margin = -75.30% (Net Income TTM -126.1m / Revenue TTM 167.5m)
Gross Margin = unknown ((Revenue TTM 167.5m - Cost of Revenue TTM 2.04m) / Revenue TTM)
Tobins Q-Ratio = 4.28 (Enterprise Value 1.81b / Total Assets 422.1m)
Interest Expense / Debt = -10.28% (Interest Expense -2.49m / Debt 24.2m)
Taxrate = 2.19% (1.17m / 53.4m)
NOPAT = -126.1m (EBIT -128.9m * (1 - 2.19%)) [loss with tax shield]
Current Ratio = 17.70 (Total Current Assets 391.3m / Total Current Liabilities 22.1m)
Debt / Equity = 0.06 (Debt 24.2m / totalStockholderEquity, last quarter 379.4m)
Debt / EBITDA = 2.32 (negative EBITDA) (Net Debt -292.6m / EBITDA -126.3m)
Debt / FCF = 2.71 (negative FCF - burning cash) (Net Debt -292.6m / FCF TTM -108.0m)
Total Stockholder Equity = 282.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.05% (Net Income -126.1m / Total Assets 422.1m)
RoE = -44.62% (Net Income TTM -126.1m / Total Stockholder Equity 282.7m)
RoCE = -42.01% (EBIT -128.9m / Capital Employed (Equity 282.7m + L.T.Debt 24.2m))
RoIC = -81.00% (negative operating profit) (NOPAT -126.1m / Invested Capital 155.6m)
WACC = 10.38% (E(2.17b)/V(2.19b) * Re(10.50%) + (debt cost/tax rate unavailable))
Discount Rate = 10.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.26%
[DCF] Fair Price = unknown (Cash Flow -108.0m)
EPS Correlation: 83.60 | EPS CAGR: 0.0% | SUE: N/A | # QB: 0
Revenue Correlation: -13.63 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=-3.15 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=-2.5% | Growth Revenue=+0.0%